Clinical Trials Logo

Advanced Pancreatic Cancer clinical trials

View clinical trials related to Advanced Pancreatic Cancer.

Filter by:

NCT ID: NCT05162118 Recruiting - Clinical trials for Advanced Pancreatic Cancer

Clinical Study of VG161 in Combination With Nivolumab in Subjects With Advanced Pancreatic Cancer

Start date: March 8, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

VG161 is a recombinant human-IL12/15/PDL1B oncolytic HSV-1 Injectable. This is a multicenter, open, single-arm design clinical trial coducted in HSV-seropositive subjects with advanced pancreatic cancer to determine the safety, tolerability and preliminary efficacy of VG161 combined with PD-1 inhibitor (Nivolumab Injection).

NCT ID: NCT05100329 Not yet recruiting - Clinical trials for Advanced Pancreatic Cancer

A Study of Mitoxantrone Hydrochloride Liposome Injection in Patients With Advanced Pancreatic Cancer

Start date: November 2021
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety, tolerability, and efficacy of mitoxantrone hydrochloride liposome injection in patients with advanced pancreatic cancer.

NCT ID: NCT05085548 Recruiting - Clinical trials for Advanced Pancreatic Cancer

ProAgio in Previously Treated Advanced Pancreatic Cancer and Other Solid Tumor Malignancies

Start date: October 29, 2021
Phase: Phase 1
Study type: Interventional

The study is a first-in-human, Phase I study to assess the safety of ProAgio in participants with advanced solid tumor malignancies including pancreatic cancer.

NCT ID: NCT05028933 Recruiting - Clinical trials for Advanced Hepatocellular Carcinoma

IMC001 for Clinical Research on Advanced Digestive System Malignancies

Start date: September 30, 2021
Phase: Phase 1
Study type: Interventional

A Phase I Clinical Study of Autologous T cells modified with chimeric antigen receptor targeting EpCAM ( EPCAM CAR-T) in Patients with malignant tumors of the digestive system (including advanced gastric cancer, colorectal cancer, liver cancer and pancreatic cancer) .

NCT ID: NCT04931381 Recruiting - Clinical trials for Advanced Pancreatic Cancer

Organoid-Guided Chemotherapy for Advanced Pancreatic Cancer

Start date: June 1, 2021
Phase: Phase 3
Study type: Interventional

The purpose of this study is to explore whether chemotherapy regimens guided by organoid drug sensitivity test can improve the outcomes of advanced pancreatic cancer. At the same time, this study will evaluate the successful stablishment rate of organoid from biopsy tissue , and explore the concordance between drug sensitivity test results and patients' treatment response.

NCT ID: NCT04928625 Recruiting - Clinical trials for Advanced Pancreatic Cancer

A Trial of SHR-A1904 in Patients With Advanced Pancreatic Cancer

Start date: August 6, 2021
Phase: Phase 1
Study type: Interventional

The study is being conducted to assess the safety and tolerability of SHR-A1904 in patients with with advanced pancreatic cancer and to determine the dose-limiting toxicity (DLT), maximum tolerated dose (MTD), and recommended phase II dose (RP2D) of SHR-A1904

NCT ID: NCT04803851 Recruiting - Clinical trials for Advanced Pancreatic Cancer

Anlotinib Plus Anti-PD-1 Antibody AK105 for Advanced Pancreatic Cancer

Start date: May 12, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This study was designed to explore the clinical efficacy of Anlotinib combined with Anti-PD-1 antibody AK105 in the treatment of third- and above -line advanced pancreatic cancer patients, in order to find a better therapy strategy for pancreatic cancer patients.

NCT ID: NCT04796948 Active, not recruiting - Clinical trials for Advanced Pancreatic Cancer

A Study of Irinotecan Liposome in Advanced Pancreatic Cancer

Start date: April 8, 2021
Phase: Phase 1
Study type: Interventional

To determine the safety and tolerability of irinotecan liposome in combination with oxaliplatin and 5-FU/LV in subjects with advanced pancreatic cancer who have not received prior systemic chemotherapy

NCT ID: NCT04707118 Not yet recruiting - Clinical trials for Advanced Pancreatic Cancer

Ntraperitoneal Thermal Perfusion Combined With Chemotherapy Versus Chemotherapy

Start date: February 23, 2021
Phase: Phase 1
Study type: Interventional

In view of the existence of malignant ascites in patients with advanced pancreatic cancer, we put forward the heat abdominal cavity perfusion chemotherapy combined albumin paclitaxel and gemcitabine compared with albumin paclitaxel and gemcitabine prospective clinical study, to assess abdominal albumin hot perfusion chemotherapy combined control of ascites and taxol in improving patients' quality of life, survival, exploring the feasibility of celiac hot perfusion chemotherapy combined albumin paclitaxel and side effects.

NCT ID: NCT04643405 Recruiting - Clinical trials for Advanced Pancreatic Cancer

APG-1387 Plus Chemotherapy in Advanced Pancreatic Adenocarcinoma

Start date: March 17, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This study is a two stage study consisting of a dose escalation phase Ib and a phase II study which include subjects with previously-treated, advanced pancreatic adenocarcinoma. Dose Limiting Toxicities (DLTs) and maximum tolerated dose (MTD) of APG1387 in combination with nab-paclitaxel and gemcitabine will be evaluated in the dose escalation phase Ib. Safety and efficacy of APG1387 plus gemcitabine and nab-paclitaxel will be evaluated in phase II.